John Leung, MD
Gastroenterology · Boston, MANPI 1447328711
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $461,903 of the $681,618 with a category attached, or 67.8%. 52 manufacturers reported payments, led by Sanofi at 37.7% of the total. 2025 is the largest year on record at $260,759, more than ten times the $15,965 reported in 2019. Among gastroenterology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,351 payments — averaging $504.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$257K
- Regeneron Healthcare Solutions, Inc.$219K
- AbbVie$51K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- Intuitive Surgical$34K
- Regeneron$16K
- plus $57K from 46 others
Across 259 payments — averaging $8304.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$665K
- AstraZeneca$575K
- Takeda Pharmaceuticals U.S.A., Inc.$168K
- Bristol Myers Squibb$146K
- QOL Medical, LLC$125K
- Shire North American Group Inc$111K
- plus $360K from 7 others
What the payments were for
- Consulting fees$102,46615%
- Speaking & faculty fees$461,90368%
- Travel & lodging$54,8198%
- Food & beverage$30,3774%
- Education$32,0535%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$681,618 in reported general payments places this provider in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 45 | $284,402 |
| RinvoqUpadacitinib | 17 | $144,624 |
| XolairOmalizumab | 21 | $86,595 |
| LinzessLinaclotide | 22 | $13,011 |
| Advair HfaFluticasone Propion/Salmeterol | 15 | $5,298 |
| Cromolyn Sodium | 29 | $4,632 |
| OdactraMite,d.Farinae-D.Pteronyssinus | 12 | $4,099 |
| CholestyramineCholestyramine (With Sugar) | 26 | $2,151 |
| Omeprazole | 56 | $771 |
| Triamcinolone Acetonide | 24 | $534 |
| Hydroxyzine Hcl | 16 | $366 |
| Azelastine Hcl | 17 | $333 |
| Famotidine | 34 | $327 |
| Ondansetron Hcl | 24 | $271 |
| Nortriptyline Hcl | 30 | $269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Linzess | $51,138 | $157,63539 claims |
| Cycle Pharmaceuticals IncCromolyn Sodium | $24 | $4,63229 claims |
| Alk-abello, IncOdactra | $144 | $4,09912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 579 gastroenterology providers in Massachusetts.
Other gastroenterology in Boston
- Hiroyuki AiharaBoston$728K
- Jessica AllegrettiBoston$696K
- Ramnik XavierBoston$567K
- Adam CheifetzBoston$512K
- Carlo TraversoBoston$447K
- Tyler BerzinBoston$215K
- Marvin RyouBoston$162K
- Nneka UfereBoston$153K
- Christopher ThompsonBoston$127K
- Scott SnapperBoston$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.